Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Apr 30;14(4):2170-2174.
doi: 10.21037/tcr-2024-2477. Epub 2025 Apr 21.

Will phenotype help guide immunotherapy in prostate cancer?

Steven Tisseverasinghe  1 , Tamim Niazi  2
Affiliations
Editorial

Will phenotype help guide immunotherapy in prostate cancer?

Steven Tisseverasinghe et al. Transl Cancer Res. .
No abstract available

Keywords: Immunotherapy; androgen deprivation therapy; prostate cancer.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-2024-2477/coif). S.T. received honoraria from Tolmar, AbbVie, Knight, Bayer, the Canadian Urological Association, and Janssen; and support for attending meetings from Tolmar, Bayer, and Janssen. He also serves as a Data Safety Monitoring Board or Advisory Board for Knight, Sumitomo, and Pfizer. T.N. received grants or contracts from Bayer, Janssen, Astellas, Tersera, and Sanofi Canada; consulting fees from AbbVie, Astellas, Janssen, Tersera, Tolmar, Bayer, AAA, Pfizer, Knight, AstraZeneca, and Sumitomo Pharma; honoraria from Merck, AbbVie, Janssen, Tolmar, AAA, Knight, Astellas, Tersera, Bayer, Pfizer, and AstraZeneca; and support for attending meetings and/or travel from Janssen, Tolmar, Knight, and Bayer. He also serves as the unpaid Chair of the Quebec GU Radiation Oncology Group and Co-Chair of the Canadian GU Radiation Oncology Group. The authors have no other conflicts of interest to declare.

Figures

Figure 1
Figure 1
Immune changes before and after ADT. ADT, androgen deprivation therapy; TME, tumor micro-environment.
See this image and copyright information in PMC

Comment on

References

    1. Shiravand Y, Khodadadi F, Kashani SMA, et al. Immune Checkpoint Inhibitors in Cancer Therapy. Curr Oncol 2022;29:3044-60. 10.3390/curroncol29050247 - DOI - PMC - PubMed
    1. Caram MEV, Ross R, Lin P, et al. Factors Associated With Use of Sipuleucel-T to Treat Patients With Advanced Prostate Cancer. JAMA Netw Open 2019;2:e192589. 10.1001/jamanetworkopen.2019.2589 - DOI - PMC - PubMed
    1. Merck Sharp & Dohme LLC. A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641). clinicaltrials.gov; 2023 Nov [cited 2024 Nov 9]. Report No.: NCT03834493. Available online: https://clinicaltrials.gov/study/NCT03834493
    1. Merck Sharp & Dohme LLC. A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (KEYNOTE-991). clinicaltrials.gov; 2024 May [cited 2024 Nov 9]. Report No.: NCT04191096. Available online: https://clinicaltrials.gov/study/NCT04191096
    1. Petrylak DP, Ratta R, Matsubara N, et al. Pembrolizumab plus docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC): Randomized, double-blind, phase 3 KEYNOTE-921 study. J Clin Oncol 2023;41:19. 10.1200/JCO.2023.41.6_suppl.19 - DOI